ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Aevi Genomic Medicine Inc

Aevi Genomic Medicine Inc (GNMX)

0.1659
0.00
( 0.00% )
Updated: 20:00:00

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
0.1659
Bid
0.1601
Ask
0.165
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
0.1659
Open
-
Last Trade
Last Trade Time
-
Average Volume (3m)
-
Financial Volume
-
VWAP
-

GNMX Latest News

No news to show yet.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 24.0192
(405.67%)
20.98M
XLOXilio Therapeutics Inc
$ 1.44
(125.35%)
27.24M
CEROCERo Therapeutics Holdings Inc
$ 2.81
(72.39%)
10.3M
BDRXBiodexa Pharmaceuticals PLC
$ 1.48
(72.29%)
79.84M
KYCHKeyarch Acquisition Corporation
$ 11.50
(64.16%)
148.04k
PMECPrimech Holdings Ltd
$ 1.48
(-61.86%)
5.39M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
GMDAGamida Cell Ltd
$ 0.039
(-34.12%)
60M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.2158
(-33.99%)
13.54M
DTSTData Storage Corporation
$ 5.8536
(-23.38%)
630.75k
NKLANikola Corporation
$ 1.015
(11.65%)
121.81M
BDRXBiodexa Pharmaceuticals PLC
$ 1.48
(72.29%)
79.84M
MARAMarathon Digital Holdings Inc
$ 23.136
(4.83%)
61.52M
AKANAkanda Corporation
$ 0.1833
(11.16%)
61.36M
GMDAGamida Cell Ltd
$ 0.039
(-34.12%)
60M

GNMX Discussion

View Posts
Mrvince Mrvince 4 years ago
That’s what it is so far that’s what I know , will serv
πŸ‘οΈ0
StocktonCA StocktonCA 4 years ago
i unfortunately did not know that. thank you for sharing, there goes my shares lol ????????
πŸ‘οΈ0
Mrvince Mrvince 4 years ago
Good news did you read what the shares will equal to so if you have 2000 shares you end up with 66 of the cerc
πŸ‘οΈ0
StocktonCA StocktonCA 4 years ago
HALTED!!! bc of MERGER!!!! Good News folks!!!!!
πŸ‘οΈ0
Chrisny73 Chrisny73 4 years ago
https://www.barchart.com/stocks/quotes/GNMX/opinion
πŸ‘οΈ0
Chrisny73 Chrisny73 4 years ago
https://www.stockscores.com/charts/charts/?ticker=gnmx
πŸ‘οΈ0
Chrisny73 Chrisny73 4 years ago
Hopefully we start to climb in after hours trading for a good week ahead
πŸ‘οΈ0
Chrisny73 Chrisny73 4 years ago
where do you see this stock headed?
πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $GNMX Video Chart 01-22-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $GNMX Video Chart 01-06-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $GNMX Video Chart 12-10-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
81vette 81vette 4 years ago
shorts getting hurt,covering on big news
πŸ‘οΈ0
dirtydozen911 dirtydozen911 4 years ago
answered my own question...…..just put up a 5 day 15 min chart......very nice ..long ,green candle, at 7:15 last night

make no mistake...THIS IS A PUMP AND DUMP !!...GLTA
πŸ‘οΈ0
dirtydozen911 dirtydozen911 4 years ago
poor performance for a bio merger announcement !!…..30 million loss, and no fund-raising going back to last jan at least....exactly what is the parent buying.....pre- clins, on crap that's years away......I was going to jump on this this morn....glad I didn`t...….this will be back at 12 cents , where it belongs......glta, and CAUTION

have the feeling this is going to get SLAMMED with a sizeable offering.
πŸ‘οΈ0
Liquid1974 Liquid1974 4 years ago
Adding GNMX
πŸ‘οΈ0
bcnuby1 bcnuby1 4 years ago
Trading paused due to pending news. glta
πŸ‘οΈ0
makinezmoney makinezmoney 4 years ago
$GNMX: NEWS.... Buyout from Cerecor !



Cerecor to Acquire Aevi Genomic Medicine
8:45 AM ET 12/5/19


4:00 PM ET 12/4/19
Symbol Last % Chg
GNMX
0.15 0.00%
Real time quote.



PHILADELPHIA, Dec. 5, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. ("Aevi") (Nasdaq: GNMX) today announced that it entered into a definitive merger agreement with Cerecor, Inc. ("Cerecor") (Nasdaq: CERC) pursuant to which Aevi will merge with a wholly owned subsidiary of Cerecor in an all-stock transaction (the "Merger") valued at approximately $16.1 million at closing, plus contingent value rights, or CVRs, for up to an additional $6.5 million in subsequent milestone payments on clinical or regulatory successes, or both. Following closing, the combined bio-pharmaceutical company will continue to be focused on pediatric orphan diseases and operate under the name Cerecor. Michael F. Cola will become Chief Executive Officer and Garry Neil will become Chief Medical Officer, of the combined company.

Deal Components

-- Cerecor will acquire all outstanding shares of Aevi stock at an aggregate

purchase price of $16.1 million less an amount by which Aevi's net assets

at closing are less than negative $1.3 million, but in no event will such

adjustment be more than $500,000. The per share price will be based on

the number of Aevi shares outstanding immediately prior to closing,

including the shares of Aevi stock to be issued to Children's Hospital of

Philadelphia Foundation upon conversion of its outstanding secured

promissory note and to AstraZeneca in connection with the exercise by

Aevi of its license option for MEDI2338, which, is anticipated to result

in an approximate per share value of $0.134 to Aevi stockholders,

assuming the maximum net asset related adjustment.

-- Cerecor will issue contingent value rights to former Aevi stockholders,

which would entitle them to an additional $2 million in cash or stock (at

Cerecor's discretion) upon the enrollment of a patient in a Phase II

study related to the AEVI-002, AEVI-006 or AEVI-007 within 24 months of

closing.

-- The contingent value rights also entitle former Aevi stockholders to an

additional $4.5 million in cash or stock (at Cerecor's discretion) upon

Food and Drug Administration (FDA) approval of a New Drug Application

(NDA) for AEVI-007 (MEDI2338) or AEVI-006 (OSI-027) within 60 months of

closing.

Benefits of the Transaction

-- Value creation through pipeline assets: The integration of Aevi's

pipeline programs should enhance the Cerecor pipeline and broaden an

already rich set of near-term inflection points for Cerecor's rare

disease portfolio, which includes the CERC-800s. Aevi's clinical-stage

programs have the potential to benefit a variety of patient populations

with significant unmet needs. Additionally, one or more of Aevi's

programs may have the potential to be eligible for a Priority Review

Voucher (PRV) granted by the FDA associated with Rare Pediatric Disease

(RPD) Designation. FDA will award priority review vouchers to sponsors

of rare pediatric disease product applications that meet certain

criteria. Under this program, a sponsor who receives an approval for a

drug or biologic for a "rare pediatric disease" (RPD) may qualify for a

voucher that can be redeemed to receive a priority review of a subsequent

marketing application for a different product.

-- AEVI-007 is a fully human anti-IL-18 monoclonal antibody with the

potential to address multiple auto-inflammatory diseases, including Adult

Onset Stills Disease (AOSD) and Multiple Myeloma (MM). IL-18 is a

pro-inflammatory cytokine; patients with AOSD and MM show elevated levels

of IL-18. Cerecor seeks to initiate a Phase 1b/2a proof-of-concept study

of AEVI-007 in ASOD and MM patients in 2020.

-- AEVI-006 is an mTORC1/2 inhibitor (a class of drugs that inhibit the

mammalian target of rapamycin) targeted towards Complex Lymphatic

Malformations (LM). LM patients often have activating mutations along

the PI3K/AKT/mTOR pathway and sirolimus is an mTORC1 inhibitor that has

demonstrated clinical utility in LM. AEVI-006 has the potential to

improve on both the safety and efficacy of mTOR inhibition in LM. Cerecor

seeks to initiate a Phase 1b/2a proof-of-concept study of AEVI-006 in LM

patients in 2020.

-- AEVI-002 is an anti-LIGHT (Lymphotoxin-like, exhibits Inducible

expression, and competes with HSV Glycoprotein D for HVEM, a receptor

expressed by T lymphocytes (part of the Tumor Necrosis Super Family 14)),

fully-human, monoclonal antibody being developed as a treatment for

Pediatric Crohn's Disease. AEVI-002 is currently in a Phase I study in

adult Crohn's patients and has recently dosed the first patient. Cerecor

anticipates initial data in the first half of 2020.

-- Aligns with Cerecor's and Aevi's transformation and innovation

strategies: Cerecor's pipeline strategy is focused on developing new

medicines for rare and orphan diseases and Aevi is focused on developing

novel therapies primarily for pediatric onset, life-altering diseases,

including rare and orphan diseases. Aevi's pipeline programs complement

Cerecor's existing pediatric rare disease pipeline led by CERC-801,

CERC-802 and CERC-803 ("CERC-800 programs"), which are therapies for

inborn errors of metabolism, specifically disorders known as Congenital

Disorders of Glycosylation. The FDA has granted RPD Designation and

Orphan Drug Designation ("ODD") to all three CERC-800 compounds, thus

qualifying Cerecor to receive a PRV upon approval of an NDA.

About the Transaction

The boards of directors of both Aevi and Cerecor have approved the proposed transaction. The consummation of the Merger is subject to customary closing conditions, including the stockholders of Aevi approving the Merger and the Securities and Exchange Commission declaring effective the registration statement on which the shares of Cerecor common stock issued in the merger will be registered. The merger is expected to close during the first quarter of 2020.

Wedbush PacGrow is acting as the exclusive strategic advisor to Aevi and Pepper Hamilton LLP is serving as its legal counsel. Wyrick Robbins Yates & Ponton LLP is serving as Cerecor's legal counsel.

About Aevi:

Aevi Genomic Medicine, Inc. is dedicated to unlocking the potential of genomic medicine to translate genetic discoveries into novel therapies. Driven by a commitment to patients with pediatric onset life-altering diseases, Aevi's research and development efforts include working with the Center for Applied Genomics (CAG) at Children's Hospital of Philadelphia to leverage novel genetic discoveries to progress its genomic medicine strategy.

About Cerecor:

Cerecor is a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases and neurological conditions. Cerecor is building a robust pipeline of innovative therapies in orphan diseases and neurology. Cerecor's pediatric rare disease pipeline is led by CERC-801, CERC-802 and CERC-803 ("CERC-800 programs"), which are therapies for inborn errors of metabolism, specifically disorders known as Congenital Disorders of Glycosylation. The FDA granted Rare Pediatric Disease Designation and Orphan Drug Designation ("ODD") to all three CERC-800 compounds, thus qualifying Cerecor to receive a Priority Review Voucher ("PRV") upon approval of a new drug application ("NDA"). The PRV may be sold or transferred an unlimited number of times. Cerecor plans to leverage the 505(b)(2) NDA pathway for all three compounds to accelerate development and approval. Cerecor is also developing one other preclinical pediatric orphan rare disease compound, CERC-913, for the treatment of mitochondrial DNA Depletion Syndrome. Cerecor's neurology pipeline is led by CERC-301, a Glutamate NR2B selective, NMDA Receptor antagonist, which Cerecor is currently exploring as a novel treatment for orthostatic hypotension. Cerecor is also developing CERC-406, a CNS-targeted COMT inhibitor for Parkinson's Disease. Cerecor also has one marketed product, Millipred(R), an oral prednisolone indicated across a wide variety of inflammatory conditions and indications.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995, including, but not limited to, Aevi's and Cerecor's expectations or predictions of future financial or business performance or conditions. Forward-looking statements are sometimes identified by their use of the terms and phrases such as "estimate," "project," "intend," "forecast," "anticipate, " "plan," "planning, "expect," "believe," "will," "will likely," "should, " "could," "would," "may" or the negative of such terms and other comparable terminology. These forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time, are difficult to predict and are generally beyond the control of either company. Actual results may differ materially from current projections.

(MORE TO FOLLOW) Dow Jones Newswires

December 05, 2019 08:45 ET (13:45 GMT)
πŸ‘οΈ0
mkt_predictor mkt_predictor 4 years ago
Careful. Reverse split coming here before end of month.
πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $GNMX Video Chart 12-04-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
wesley_ wesley_ 4 years ago
$.175 nice
πŸ‘οΈ0
PennyWorld PennyWorld 4 years ago
So, just curious... how did the June 2019 R/S work out?
πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $GNMX Video Chart 09-13-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
pberger pberger 5 years ago
Earnings are out, https://www.sec.gov/cgi-bin/viewer?action=view&cik=1138776&accession_number=0001144204-19-039522&xbrl_type=v#
and beats forecast by $.04 (-0.06 vs -0.1).
GLTA
πŸ‘οΈ0
shurtha2000 shurtha2000 5 years ago
Bought some nice size
πŸ‘οΈ0
pberger pberger 5 years ago
Indeed, I was wondering too.

Btw, so far (8 AM) no trade activity at all in premarket but the stock is not halted, hmm...
πŸ‘οΈ0
Widowsson32 Widowsson32 5 years ago
Company has a market cap of 13 million so why does the 8K says that NASDAQ staff advise them that they do not qualify to be listed on NASDAQ due to market cap less than 10 million dollars
πŸ‘οΈ0
pberger pberger 5 years ago
Where are the earnings?
Why they are not produced and what to expect from tomorrow presentation?
See https://www.prnewswire.com/news-releases/aevi-genomic-medicine-to-present-at-the-2019-wedbush-pacgrow-healthcare-conference-300897117.html
πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $GNMX Video Chart 08-08-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $GNMX Video Chart 08-07-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
Snowman2 Snowman2 5 years ago
Yes it is :)
πŸ‘οΈ0
allezlOM allezlOM 5 years ago
...and power hour :)
πŸ‘οΈ0
Snowman2 Snowman2 5 years ago
I love this Stock
πŸ‘οΈ0
wesley_ wesley_ 5 years ago
grats & bye, I'm still adding on any dip :)
πŸ‘οΈ0
cjstocksup cjstocksup 5 years ago
Just sold my pre market GNMX .189's at .295. A bit premature but I have to leave and better safe than sorry. his AM started slow but dang solid run once we broke .21. GL everyone.
πŸ‘οΈ0
Prominent Capital Prominent Capital 5 years ago
Guys have anyone read the news for the agreement with
astra Zeneca ? What does this mean for the perspective of the company ?
πŸ‘οΈ0
stock1ace1 stock1ace1 5 years ago
Full on breakout .28s going
πŸ‘οΈ0
wesley_ wesley_ 5 years ago
nice volume
πŸ‘οΈ0
stock1ace1 stock1ace1 5 years ago
.26s up
πŸ‘οΈ0
420man 420man 5 years ago
Read the news.... Aevi has to raise funds for the license in the single digit millions.. Love that line in the PR! LOL. That means funding round prior to RS approval in September. POS
πŸ‘οΈ0
hedge_fun hedge_fun 5 years ago
Under the terms of the License Agreement, the Company has exclusive license rights for the worldwide development and commercialization of Astellas’ second generation mTORC1/2 inhibitor, ASP7486 (OSI-027) (individually, an β€œ OSI Product ” and collectively, the β€œ OSI Products ”). Pursuant to the terms of the Royalty Agreement, in exchange for a one-time aggregate payment of $2,000,000 (the β€œ Purchase Price ”) made by the Investors to the Company, the Company will pay to the Investors, on a quarterly basis during the term of the Royalty Agreement, an aggregate amount equal to a low-single digit percentage of the aggregate net sales of the OSI Products for such quarter (the β€œ Royalty Amount ”). The Royalty Amount will be paid to each Investor based on such Investor’s pro rata percentage of the Purchase Price. At any time beginning three years after the date of the first public launch of an OSI Product (the β€œ Buyout Payment Date ”), the Company may exercise, at its sole discretion, a buyout option that terminates the Company’s further obligations under the Royalty Agreement in exchange for a payment to Investors of an aggregate of 75% of the net present value of the royalty payments (as determined by a mutually agreeable independent valuation firm) otherwise likely to be due under the Royalty Agreement from the Buyout Payment Date through the later of the end of data regulatory exclusivity and the date upon which the last of the patents relating to the OSI Products expire.

https://ih.advfn.com/stock-market/NASDAQ/aevi-genomic-medicine-inc-GNMX/stock-news/80365916/current-report-filing-8-k
πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $GNMX Video Chart 07-16-2019 * *

Link to Video - click here to watch the technical chart video
πŸ‘οΈ0
pauljack13 pauljack13 5 years ago
I sold this this morning at break even right before the big move. Bad timing.
πŸ‘οΈ0
Fat Thor Fat Thor 5 years ago
Big news out.
πŸ‘οΈ0
420man 420man 5 years ago
Waking up??
πŸ‘οΈ0
420man 420man 5 years ago
Totally agree! I'm out as well, and for good. On to more promising trades. GL
πŸ‘οΈ0
mkt_predictor mkt_predictor 5 years ago
I sold the rest of my shares last Friday. Will keep on watch though for any updates.
πŸ‘οΈ0
420man 420man 5 years ago
GNMX--- You're the only stock that's abused my capital this much and this long...get UR shizzz together here and let her run!!! It's time already.
πŸ‘οΈ0
mkt_predictor mkt_predictor 5 years ago
Welcome back. Yeah, I’m planning to hold through May at minimum to see what if anything our recent volume spike was about.
πŸ‘οΈ0
420man 420man 5 years ago
Agreed...news is the only way this makes an upward and significant move within the next few weeks.

I have an very strong feeling they are going to run this up hard (news of positive testing results) prior to the June 23rd date, which they can THEN seek new Tute funding to further their tests...AND, based on their aggrement with the Hospital that is currently their only substantial investor, I conclude that they want to make them very happy for their investment thus far.


This WILL run BIG and soon....just gotta clear your mind of how the stock has performed the past several months or you will sell way too soon! It's a game, that I'm confident you are fully aware of.


If that scenario fails to unfold, then I firmly believe they will run it post RS. My money is that they will run it now!

I was tired of holding last week, but I'm refreshed and re-entered today.
πŸ‘οΈ0
mkt_predictor mkt_predictor 5 years ago
What makes you think that? I think only news at this point will get this back to .30s.
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock